Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

Literature DB >> 29076126

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

Rebeca Manso¹, Margarita Sánchez-Beato², Julia González-Rincón^2,3, Sagrario Gómez², Federico Rojo¹, Manuela Mollejo^3,4, Mónica García-Cosio^3,5, Javier Menárguez^3,6, Miguel A Piris^1,3, Socorro M Rodríguez-Pinilla^1,3.

Abstract

Entities: Disease

Keywords: zzm321990PTCLzzm321990; zzm321990TFHzzm321990; JAK/STAT; NF-KB; expression; mutation; prognosis

Mesh：

Substances：

Year: 2017 PMID： 29076126 DOI： 10.1111/bjh.14984

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

1. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Authors: Tammy Linlin Song; Maarja-Liisa Nairismägi; Yurike Laurensia; Jing-Quan Lim; Jing Tan; Zhi-Mei Li; Wan-Lu Pang; Atish Kizhakeyil; Giovani-Claresta Wijaya; Da-Chuan Huang; Sanjanaa Nagarajan; Burton Kuan-Hui Chia; Daryl Cheah; Yan-Hui Liu; Fen Zhang; Hui-Lan Rao; Tiffany Tang; Esther Kam-Yin Wong; Jin-Xin Bei; Jabed Iqbal; Nicholas-Francis Grigoropoulos; Siok-Bian Ng; Wee-Joo Chng; Bin-Tean Teh; Soo-Yong Tan; Navin Kumar Verma; Hao Fan; Soon-Thye Lim; Choon-Kiat Ong
Journal: Blood Date: 2018-07-27 Impact factor: 22.113

Review 2. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.

Authors: Zachary Braunstein; Miguel Ruiz; Walter Hanel; Polina Shindiapina; John C Reneau; Jonathan E Brammer
Journal: J Pers Med Date: 2022-06-13

Review 3. Peripheral T cell lymphomas: from the bench to the clinic.

Authors: Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal: Nat Rev Cancer Date: 2020-04-06 Impact factor: 60.716

4. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.

Authors: Jing Jing Han; Megan O'byrne; Mary J Stenson; Matthew J Maurer; Linda E Wellik; Andrew L Feldman; Ellen D McPhail; Thomas E Witzig; Mamta Gupta
Journal: Blood Cancer J Date: 2018-11-12 Impact factor: 11.037

5. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Authors: Matthew J Reilley; Patricia McCoon; Carl Cook; Paul Lyne; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Michael Curran; Qinying Liu; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod; David S Hong
Journal: J Immunother Cancer Date: 2018-11-16 Impact factor: 13.751

6. JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis.

Authors: Kang Le; Linda E Wellik; Matthew J Maurer; Ellen D McPhail; Thomas E Witzig; Mamta Gupta
Journal: Blood Cancer J Date: 2021-03-12 Impact factor: 11.037

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

1. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Review 2. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.

Review 3. Peripheral T cell lymphomas: from the bench to the clinic.

4. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.

5. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

6. JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis.

7. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.

Review 8. Targeted Approaches to T-Cell Lymphoma.

9. STAT3 Mutation Is Associated with STAT3 Activation in CD30⁺ ALK^- ALCL.

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.

1. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Review 2. Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.

Review 3. Peripheral T cell lymphomas: from the bench to the clinic.

4. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.

5. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

6. JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis.

7. Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.

Review 8. Targeted Approaches to T-Cell Lymphoma.

9. STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK- ALCL.

9. STAT3 Mutation Is Associated with STAT3 Activation in CD30⁺ ALK^- ALCL.